Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran

American Heart Journal

Volumn 157, Issue 5, 2009, Pages

  Ezekowitz, Michael D ^a   Connolly, Stuart ^b   Parekh, Amit ^a   Reilly, Paul A ^c   Varrone, Jeanne ^c   Wang, Susan ^c   Oldgren, Jonas ^d   Themeles, Ellison ^b   Wallentin, Lars ^d   Yusuf, Salim ^b  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; DIPYRIDAMOLE; TICLOPIDINE; VERAPAMIL; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EMBOLISM; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; STROKE; UNSPECIFIED SIDE EFFECT;

EID: 64349107688     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.02.005     Document Type: Article

References (27)

1. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from 5 randomized controlled trials. Arch Intern Med 154 (1994) 1449-1457
2. Schwarz U., Ritchie M., Bradford Y., et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 358 (2008) 999-1008
3. Brass L., Krumholz L., Scinto J., et al. Warfarin use following ischemic stroke among medicare patients with atrial fibrillation. Arch Intern Med 158 (1998) 2093-2100
4. Executive Steering Committee for the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation: randomised controlled trial. Lancet 362 (2003) 1691-1698
5. Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs. warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. J Am Med Assoc 293 (2005) 690-698
6. The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus ASA versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367 (2006) 1903-1912
7. Samsa G., Matchar D., Goldstein L., et al. Quality of anticoagulation management among patients with atrial fibrillation. Arch Intern Med 160 (2000) 967-973
8. The Amadeus investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 371 (2008) 315-321
9. Stassen J., Rathgen K., Zimmermann R., et al. Pharmacodynamics of the synthetic direct thrombin inhibitor BIBR 953 ZW in healthy subjects. Thromb Haemost Suppl. (2001) OC2347 [Abstract]
10. Ezekowitz M., Reilly P., Nehmiz G., et al. Dabigatran with or without concomitant ASA compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 100 (2007) 1419-1426
11. The PETRO-EX Investigators. Safety and efficacy of extended exposure to several doses of a new oral direct thrombin inhibitor dabigatran etexilate in atrial fibrillation. Cerebrovasc Dis 21 Supplment 4 (2006) 5, 2 [Abstract]
12. Eriksson B., Dahl O., Ahnfelt L., et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement. BISTRO I. J Thromb Haemost 2 (2004) 1573-1580
13. Eriksson B., Dahl O., Büller H., et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: The BISTRO II randomized trial. J Thromb Haemost 3 (2005) 103-111
14. Rosendaal F., Cannegieter S., van der Meer F., et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69 (1993) 236-239
15. Benjamini Y., and Hochberg T. Multiple hypotheses testing with weights. Scand J Statist 24 (1997) 407-418
16. Ezekowitz M. Anticoagulation interruptus: not without risk. Circulation 110 (2004) 1518-1519
17. Petersen P., Boysen G., Godtfredsen J., et al. Placebo-controlled, randomised trial of warfarin and ASA for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1 (1989) 175-179
18. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in nonrheumatic atrial fibrillation. N Engl J Med 323 (1990) 1505-1511
19. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study. Final results. Circulation 84 (1991) 527-539
20. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet 342 (1993) 1255-1262
21. Ezekowitz M.D., Bridgers S.L., James K.E., et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation: the Veterans Affairs Cooperative Study. N Engl J Med 327 (1992) 1406-1412
22. Connolly S.J., Laupacis A., Gent M., et al. Canadian atrial fibrillation anticoagulation study. J Am Coll Cardiol 18 (1991) 349-355
23. Eriksson B., Dahl O., Rosencher N., et al., for the RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370 (2007) 949-956
24. Eriksson B., Dahl O., Rosencher N., et al., for the RE-MODEL study group. A new oral anticoagulant, dabigatran etexilate, is effective and safe in preventing venous thromboembolism after total knee replacement surgery. J Thromb Haemost 5 (2007) 2178-2185
25. Brinker A., He R., Desai M., et al. Safety of ximelagatran. J Am Med Assoc 293 (2005) 2859
26. Astrazeneca Receives Action Letter From FDA For Exanta (Ximelagatran), Astrazeneca press release, 2004.
27. Albers G., and on behalf of SPORTIF Investigators. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials. Am J Manag Care 10 (2004) S462-S473